Skip to content
karyopharm-logo
Logo for Karyopharm
Main Menu
Contact
Clinical Trials
Careers
Follow Us
LinkedIn
Twitter
Search
About
Show submenu
About Karyopharm
Management Team
Board of Directors
Scientific Advisory Board
Media Center
Events & Webinars
Careers
Patients & Families
Show submenu
Overview
Multiple Myeloma
SINE Technology
Diffuse Large B-Cell Lymphoma (DLBCL)
Clinical Trials
Patient Resources
Healthcare Professionals
Show submenu
SINE Technology (Selective Inhibitor of Nuclear Export)
Healthcare Provider Resources
Supporting Medical Research
Publications and Presentations
Karyopharm Expanded Access Program
Grants and Giving
Products
Pipeline
Show submenu
Overview
Oral Selinexor
Oral Eltanexor
Oral Dual Inhibitor of PAK4 and NAMPT (KPT-9274)
Oral Verdinexor
Investors
Show submenu
Corporate Profile
Press Releases
Events & Presentations
Corporate Governance
Show submenu
Management Team
Board of Directors
Committee Composition
Contact the Board
Financial Information
Show submenu
SEC Filings
Annual Reports & Proxy Statements
Quarterly Results
Key Ratios
Stock Information
Show submenu
Interactive Chart
Investment Calculator
Historical Stock Price
Analyst Coverage
Investor FAQs
Corporate Sustainability
Contact Us
Show submenu
Investor Alerts
RSS
Targeting Cancer at the Nuclear Pore
Targeting Cancer at the Nuclear Pore
Learn More